Crohn's disease (moderate to severe) - vedolizumab: committee papers
Table of contents
Committee papers part 1
01. Pre-Meeting Briefing prepared by NICE
02. Submission from the technology manufacturer - Takeda
03. NICE request to the manufacturer for clarification on their submission
04. NICE request to the manufacturer for additional clarification on their submission
05. Manufacturer clarification response
Committee papers part 2
06. Consultee submission - British Society of Gastroentrology
07. Consultee submission - Crohns and Colitis UK
08. Consultee submission - Royal College of Physicians
09. Consultee submission - United Clinical Pharmacy Association
10. Patient expert personal perspective - Battersby
11. Patient expert personal perspective - Phillips
12. Clinical expert statement declaration - Murphy
13. Clinical expert statement declaration - Sanderson
14. Evidence Review Group report prepared by School of Health Related Research, University of Sheffield
15. Evidence Review Group report - Updated pages
16. Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. If required, please download Adobe Reader here.
This page was last updated: 12 January 2015